Does Limited-Margin Radiotherapy Change the Recurrence Pattern and Survival of Patients With IDH-Wild-Type Glioblastoma? Analysis and Validation of a Different Approach.
Volkan Semiz, Oguz Cetinayak, Barbaros Aydın, Seyda Kınay, Dogukan Akcay, Nuri Karabay, Fadime Akman Can
{"title":"Does Limited-Margin Radiotherapy Change the Recurrence Pattern and Survival of Patients With IDH-Wild-Type Glioblastoma? Analysis and Validation of a Different Approach.","authors":"Volkan Semiz, Oguz Cetinayak, Barbaros Aydın, Seyda Kınay, Dogukan Akcay, Nuri Karabay, Fadime Akman Can","doi":"10.1111/ajco.70014","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>We aimed to analyze our radiotherapy protocol by evaluating its effect on recurrence patterns and survival outcomes.</p><p><strong>Methods: </strong>We assessed 69 patients diagnosed with IDH-wild-type glioblastoma who underwent chemoradiotherapy at our institution from January 2014 to January 2021. A high-risk clinical target volume (CTV<sub>high</sub>) was created with a 1 cm margin in all directions from the GTV, while a low-risk clinical target volume (CTV<sub>low</sub>) was established with a 2 cm margin. Planned treatment volumes with a 2-3 mm margin in all directions were created, and doses of 60 and 50 Gy were prescribed in 30 fractions. Recurrence patterns were classified as central, in-field, marginal, or distant based on the 60 and 50 Gy D95 isodose lines.</p><p><strong>Results: </strong>With a median follow-up of 21 months, 88.4% of patients experienced recurrence. The overall survival rates at 1, 2, and 5 years were 84.1%, 51.5%, and 17%, respectively. The progression-free survival rates at the same intervals were 44.9%, 21.5%, and 9.5%, respectively. Recurrence patterns were central in 63.9%, in-field in 18%, marginal in 4.9%, and distant in 13.1%.</p><p><strong>Conclusion: </strong>The recurrence pattern remained unchanged with our protocol. With longer survival times, distant recurrence rates increase, yet central and in-field recurrences remain dominant. Despite the decrease in the volume that received the 60 Gy dose, marginal recurrences remained at a notably low level.</p>","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":1.6000,"publicationDate":"2025-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Asia-Pacific journal of clinical oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/ajco.70014","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Purpose: We aimed to analyze our radiotherapy protocol by evaluating its effect on recurrence patterns and survival outcomes.
Methods: We assessed 69 patients diagnosed with IDH-wild-type glioblastoma who underwent chemoradiotherapy at our institution from January 2014 to January 2021. A high-risk clinical target volume (CTVhigh) was created with a 1 cm margin in all directions from the GTV, while a low-risk clinical target volume (CTVlow) was established with a 2 cm margin. Planned treatment volumes with a 2-3 mm margin in all directions were created, and doses of 60 and 50 Gy were prescribed in 30 fractions. Recurrence patterns were classified as central, in-field, marginal, or distant based on the 60 and 50 Gy D95 isodose lines.
Results: With a median follow-up of 21 months, 88.4% of patients experienced recurrence. The overall survival rates at 1, 2, and 5 years were 84.1%, 51.5%, and 17%, respectively. The progression-free survival rates at the same intervals were 44.9%, 21.5%, and 9.5%, respectively. Recurrence patterns were central in 63.9%, in-field in 18%, marginal in 4.9%, and distant in 13.1%.
Conclusion: The recurrence pattern remained unchanged with our protocol. With longer survival times, distant recurrence rates increase, yet central and in-field recurrences remain dominant. Despite the decrease in the volume that received the 60 Gy dose, marginal recurrences remained at a notably low level.
期刊介绍:
Asia–Pacific Journal of Clinical Oncology is a multidisciplinary journal of oncology that aims to be a forum for facilitating collaboration and exchanging information on what is happening in different countries of the Asia–Pacific region in relation to cancer treatment and care. The Journal is ideally positioned to receive publications that deal with diversity in cancer behavior, management and outcome related to ethnic, cultural, economic and other differences between populations. In addition to original articles, the Journal publishes reviews, editorials, letters to the Editor and short communications. Case reports are generally not considered for publication, only exceptional papers in which Editors find extraordinary oncological value may be considered for review. The Journal encourages clinical studies, particularly prospectively designed clinical trials.